REFERENCES
1. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165-3241.
2. Bateman BT, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol 2012;206:134 e131-138.
3. Orbach H, Matok I, Gorodischer R, et al. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol 2013;208:301 e301-306.
4. Zetterström K, Lindeberg SN, Haglund B, et al. Maternal complications in women with chronic hypertension: a population-based cohort study. Acta Obstet Gynecol Scand 2005;84:419-424.
5. Su CY, Lin HC, Cheng HC, et al. Pregnancy outcomes of anti-hypertensives for women with chronic hypertension: a population-based study. PLoS One 2013;8:e53844.
6. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol 2019;133:e26-e50.
7. Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133]. 2019. (Accessed May 14, 2020, at https://www.nice.org.uk/guidance/ng133.)
8. Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2018;13:291-310.
9. Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018;10:CD002252.
10. Rezk M, Emarh M, Masood A, et al. Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial. Hypertens Pregnancy 2020;39:393-398.
11. Magee LA, Singer J, von Dadelszen P, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015;372:2367-2368.
12. Magee LA, Group CS, von Dadelszen P, et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG 2016;123:1143-1151.
13. Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. beta-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2012;2.
14. Hoeltzenbein M, Beck E, Fietz AK, et al. Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension 2017;70:201-208.
15. Nakhai-Pour HR, Rey E, Bérard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol 2010;89:147-154.
16. Ray JG, Vermeulen MJ, Burrows EA, et al. Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster Outcome Study of Hypertension In Pregnancy 2 (MOS HIP 2). BMC Pregnancy Childbirth 2001;1:6.
17. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012;16:37-41.
18. Pocobelli G, Yu O, Fuller S, et al. One-Step Approach to Identifying Gestational Diabetes Mellitus: Association With Perinatal Outcomes. Obstet Gynecol 2018;132:859-867.
19. Chen L, Pocobelli G, Yu O, et al. Early Pregnancy Hemoglobin A1C and Pregnancy Outcomes: A Population-Based Study. Am J Perinatol 2019;36:1045-1053.
20. Lawrence JM, Andrade SE, Avalos LA, et al. Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007. Obstet Gynecol 2013;121:106-114.
21. Hansen C, Andrade SE, Freiman H, et al. Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. Pharmacoepidemiol Drug Saf 2016;25:170-178.
22. Andrade SE, Scott PE, Davis RL, et al. Validity of health plan and birth certificate data for pregnancy research. Pharmacoepidemiol Drug Saf 2013;22:7-15.
23. Baldwin E, Johnson K, Berthoud H, et al. Linking mothers and infants within electronic health records: a comparison of deterministic and probabilistic algorithms. Pharmacoepidemiol Drug Saf 2015;24:45-51.
24. Lydon-Rochelle MT, Holt VL, Cardenas V, et al. The reporting of pre-existing maternal medical conditions and complications of pregnancy on birth certificates and in hospital discharge data. Am J Obstet Gynecol 2005;193:125-134.
25. Lydon-Rochelle MT, Holt VL, Nelson JC, et al. Accuracy of reporting maternal in-hospital diagnoses and intrapartum procedures in Washington State linked birth records. Paediatr Perinat Epidemiol 2005;19:460-471.
26. Chen L, Shortreed SM, Easterling T, et al. Identifying hypertension in pregnancy using electronic medical records: The importance of blood pressure values. Pregnancy Hypertens 2020;19:112-118.
27. Oken E, Kleinman KP, Rich-Edwards J, et al. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003;3:6.
28. Palmsten K, Huybrechts KF, Kowal MK, et al. Validity of maternal and infant outcomes within nationwide Medicaid data. Pharmacoepidemiol Drug Saf 2014;23:646-655.
29. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol 2019;133:e1-e25.
30. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
31. Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med 2016;35:5642-5655.
32. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
33. Robins JM. Marginal Structural Models versus Structural nested Models as Tools for Causal inference. In: Halloran ME, Berry D, eds. Statistical Models in Epidemiology, the Environment, and Clinical Trials. New York, NY: Springer New York; 2000:95-133.
34. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-3107.
35. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661-3679.
36. LeFevre ML, Force USPST. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:819-826.
37. Webster LM, Myers JE, Nelson-Piercy C, et al. Labetalol Versus Nifedipine as Antihypertensive Treatment for Chronic Hypertension in Pregnancy: A Randomized Controlled Trial. Hypertension 2017;70:915-922.
38. Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet 2019;394:1011-1021.
39. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol 2019;133:e26-e50.
40. Innes A, Gemmell HG, Smith FW, et al. The short term effects of oral labetalol in patients with chronic renal disease and hypertension. J Hum Hypertens 1992;6:211-214.
41. Sanders GL, Davies DM, Gales GM, et al. A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol 1979;8:149s-151s.
42. Wallin JD, Wilson D, Winer N, et al. Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial. Am J Med 1983;75:87-94.